Liquid Biopsy Global Market Report 2024

The liquid biopsy market size has grown exponentially in recent years. It will grow from $6.61 billion in 2023 to $8.64 billion in 2024 at a compound annual growth rate (CAGR) of 30.8%. The growth observed during the historical period can be attributed to several key factors, including significant advances in cancer research, the appeal of non-invasive diagnostic methods, the emergence of personalized medicine, regulatory approvals for liquid biopsy tests, and the emphasis on early cancer detection. These factors collectively contributed to the growth of the liquid biopsy market during that period.

The liquid biopsy market size is expected to see exponential growth in the next few years. It will grow to $27.44 billion in 2028 at a compound annual growth rate (CAGR) of 33.5%. The anticipated growth in the forecast period can be attributed to several key factors, including the expanding range of applications for liquid biopsy, the increasing use of liquid biopsy for cancer monitoring, the development of emerging technologies in the field, the use of liquid biopsy as companion diagnostics, and its role in biomarker discovery. Major trends expected to shape this period include the continued development of liquid biopsy for cancer detection and monitoring, its application in therapeutic monitoring, its use in minimal residual disease (MRD) monitoring, and its extension to non-oncological applications, reflecting the evolving landscape of this diagnostic technology.

Government funding allocated for the advancement of cancer detection is a key driver in the growth of the liquid biopsy market. Such funding aids researchers in their efforts for drug discovery, diagnosing diseases like cancer, and developing treatments. For example, in 2021, the National Cancer Institute (NCI), a US-based government agency, increased its grant allocation to $678,000 from $570,000 in 2020. Additionally, in 2022, the National Institute of Health (NIH) was granted $46.6 billion, with $6.9 billion allocated to the National Cancer Institute (NCI) specifically for the progression of cancer research. Thus, these governmental funds play a crucial role in fostering the liquid biopsy market's growth.

The primary product types within the liquid biopsy market encompass assay kits, instruments, and services. Assay kits provide the necessary reagents and components for conducting analytical tests, which are used in various industries such as food, cereals and dietary fiber, dairy, analytical laboratories, animal feed and nutrition, biofuels, biotechnology, wine, malting and brewing, and research. Liquid biopsy has numerous clinical applications, including early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring, which are utilized by reference laboratories, hospitals and physician laboratories, and academic and research centers in the field of orthopedics and oncology, among others.

The liquid biopsy market research report is one of a series of new reports that provides liquid biopsy market statistics, including liquid biopsy industry, regional shares, competitors with a liquid biopsy market share, detailed liquid biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the liquid biopsy industry. This liquid biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rising incidence of cancer is expected to drive the expansion of the liquid biopsy market. Cancer, characterized by uncontrolled cell growth and invasive tendencies, is detectable through liquid biopsy methods. These techniques identify cancer-specific biomarkers like circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in a patient's blood sample, enabling non-invasive diagnosis and monitoring. For instance, the American Cancer Society Inc. projects an increase in newly diagnosed cancer cases in the USA, from over 1,918,030 cases in 2022 to an estimated 1,958,310 cases in 2023. This surge in cancer prevalence serves as a driver for the liquid biopsy market's growth.

The lack of clear regulations governing laboratory developed tests (LDT) in the field of liquid biopsy poses a significant challenge. Laboratory developed tests (LDTs) are diagnostic tests created and intended for clinical use within a single laboratory. Uncertain U.S. FDA regulations for these tests, such as those for liquid biopsy, create delays in test approvals, potentially hindering the growth of the liquid biopsy market.

Businesses are rapidly adapting to new market demands and are notably prioritizing the launch of cutting-edge products within the liquid biopsy sector. This initiative aims to address the ever-increasing requirement for liquid biopsy products and services, augmenting their revenue and establishing a competitive advantage over their competitors. As an example, in June 2023, Laboratory Corporation of America Holdings, a US-based healthcare company, introduced Labcorp Plasma Focus, a liquid biopsy test engineered for identifying cancer-associated biomarkers in individuals with advanced or metastatic solid tumors. The test leverages the analysis of cell-free DNA (cfDNA) present in a patient's blood sample, constructing a detailed genomic profile of their tumor. This approach equips oncologists to refine patient healthcare management by creating personalized and precisely targeted therapy strategies.

Prominent companies involved in the liquid biopsy market are dedicating their efforts to the development of extensive liquid biopsy panels to gain a competitive edge. These extensive liquid biopsy panels serve as advanced diagnostic tools, analyzing various biomarkers within a patient's blood sample to detect and monitor a wide array of diseases, notably cancer. For instance, in June 2022, Tempus Labs Inc., a US-based technology company focused on precision medicine through artificial intelligence, announced the introduction of xF+, the most expansive liquid biopsy panel clinically available. This panel covers a broader range of genes, including single nucleotide variants, indels in all genes, and an expanded coverage of translocations, gene rearrangements, and copy number variants. Additionally, the xF+ panel evaluates blood-based tumor mutational burden (bTMB) and microsatellite instability, providing essential predictive biomarkers for various cancer immunotherapies' efficacy.

In June 2021, Quest Diagnostics, a US-based clinical laboratory, acquired Haystack Oncology Inc. for an undisclosed amount. This acquisition enables the incorporation of MRD liquid biopsy technology into Quest Diagnostics' cancer diagnostics portfolio. It serves to detect residual or recurring cancer in its early stages, providing guidance for enhanced treatment decisions. Haystack Oncology Inc. specializes in liquid biopsy services.

Major companies operating in the liquid biopsy market include QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Menarini Silicon Biosystems, Biocept Inc., Janssen Diagnostics LLC, Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE PLC, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Guardant Health AMEA, Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.

North America was the largest region in the liquid biopsy market in 2023. Western Europe was the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The liquid biopsy market includes revenues earned by entities by DNA collection tubes, tests, and reagents. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.